This matrix-based strategy was used to screen ABC-DLBCL cell lines for sensitivity to the BCR inhibitor ibrutinib in combination with nearly 500 established or investigational anti-cancer compounds [233]. The gene discussed is BCR; the disease is aneurysmal bone cyst.